Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical

Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical

Background: Excessive plasma histamine concentrations cause symptoms in mast cell activation syndrome, mastocytosis, or anaphylaxis. Anti-histamines are often insufficiently efficacious. Human diamine oxidase (hDAO) can rapidly degrade histamine and therefore represents a promising new treatment str...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Elisabeth Gludovacz, Kornelia Schuetzenberger, Marlene Resch, Katharina Tillmann, Karin Petroczi, Markus Schosserer, Sigrid Vondra, Serhii Vakal, Gerald Klanert, Jürgen Pollheimer, Tiina A Salminen, Bernd Jilma, Nicole Borth, Thomas Boehm
Formato: article
Lenguaje:EN
Publicado: eLife Sciences Publications Ltd 2021
Materias:
diamine oxidase
histamine
heparin
heparan sulfate proteoglycan
clearance
half-life
Medicine
R
Science
Q
Biology (General)
QH301-705.5
Acceso en línea:https://doaj.org/article/d7281aa1f5af4be284b2a714515c12fb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/d7281aa1f5af4be284b2a714515c12fb

Ejemplares similares